For first phase of Mounjaro's obesity rollout in England, only a limited number of patients will have access

Following its endorsement of Eli Lilly’s obesity medicine tirzepatide, England’s National Institute for Health and Care Excellence (NICE) has laid out plans for an unprecedented phased rollout that will limit the number eligible patients for three years.